Induction therapy for adults with acute lymphoblastic leukemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

Blood

Volumn 106, Issue 12, 2005, Pages 3760-3767

  Rowe, Jacob M ^a   Buck, Georgina ^b   Burnett, Alan K ^b   Chopra, Raj ^b   Wiernik, Peter H ^b   Richards, Susan M ^b   Lazarus, Hillard M ^b   Franklin, Ian M ^b   Litzow, Mark R ^b   Ciobanu, Niculae ^b   Prentice, H Grant ^b   Durrant, Jill ^b   Tallman, Martin S ^b   Goldstone, Anthony H ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CELL LINEAGE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LEUKOCYTE COUNT; LOW DRUG DOSE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIBLING; T LYMPHOCYTE; THROMBOSIS; TUMOR CELL DESTRUCTION; WHOLE BODY RADIATION;

EID: 28444490353     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1623     Document Type: Article

References (42)

1. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (aminopterin). N Engl J Med. 1948;238:787-792.
2. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
3. Silverman LB, Gelber RD, Dalton VK, et al. Approved outcome for children with acute lymphoblastic leukemia: results of Dana Farber Consortium protocol 91-01. Blood. 2001;97:1211-1218.
4. Schauer P, Arlin ZA, Mertelsmann R, et al. Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol. 1983;1:462-470.
5. Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71:123-131.
6. Larson RA, Dodge RK, Burns CP, et al. A fivedrug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025-2037.
7. Taylor PR, Reid MM, Bown N, et al. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood. 1992;80:1813-1817.
8. Chessells JM, Hall E, Prentice HG, et al. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998;12:463-473.
9. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14:1307-1325.
10. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547-561.
11. Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia. 2001;15:208-216.
12. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMAALL 0288 randomized study. Blood. 2002;99:863-871.
13. Linker C, Damon L, Ries C, Navarro W. Intensi-fied and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:2464-2471.
14. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104:3028-3037.
15. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075-4086.
16. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy is a predictor of disease-free survival and late recurrence of child acute lymphoblastic leukemia: a report of Children's Cancer Study Group. J Clin Oncol. 1989;7:1807-1815.
17. Laughton SJ, Ashton LJ, Kwan E, et al. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2264-2271.
18. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood. 1999;93:3983-3993.
19. Cytogenetic abnormalities in adult acute lympoblastic leukemia: correlations with hematologic findings outcome: a Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood. 1996;87:3135-3142.
20. Maurer J, Janssen JW, Thiel E, et al. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction. Lancet. 1991;337:1055-1058.
21. Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood. 1992;80:2983-2990.
22. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99:1536-1543.
23. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood. 1995;5:1151-1168.
24. Hoelzer DF. Diagnosis and treatment of adult acute lymphoblastic leukemia. In: Wiernik PH, Canellos GP, Dutcher JP, Kyle RA, eds. Neoblastic Diseases of the Blood. 3rd ed. New York, NY: Churchill Livingstone; 1996:295-316
25. Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol. 1997;24:70-82.
26. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma. Blood. 1986;68:1-31.
27. Boucheix C, David B, Sebban C, et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87): French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood. 1994;84:1603-1612.
28. Baumer JH, Mott MG, Gentle TA. Sex and prognosis in childhood acute lymphoblastic leukaemia [letter]. Lancet. 1978;2:673.
29. Hammond D, Sather H, Nesbit M, et al. Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14:124-134.
30. Chessells JM, Richards SM, Bailey CC, et al. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol. 1995;89:364-372.
31. Shuster JJ, Wacker P, Pullen J, et al. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16:2854-2863.
32. Pui CH, Boyett JM, Relling MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17:818-824.
33. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assn. 1958;53:457-481.
34. Goldstone AH, Chopra R, Buck G, et al. The outcome of 267 Philadelphia-positive adults in the International UKALL XII/ECOG E2993 study: final analysis and the role of allogeneic transplant in those under 50 years [abstract]. Blood. 2003;104:268a.
35. Gaynor J, Chapman D, Little C, et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol. 1988;6:1014-1030.
36. Lamanna N, Weiss M. Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia. Curr Hematol Rep. 2004;3:40-46.
37. Cataland SR, Daugherty CK, Weseman EC, Larson RA. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2001;41:297-307.
38. Weiss MA, Heffner, Lamanna N, et al. A randomized trial of cytarabine and high-dose mitoxantrone compared to a standard vincristine-prednisone-based regimen as induction therapy for adult patients with ALL [abstract]. Proc Am Soc Clin Oncol. 2005;23:574s.
39. Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20:1094-1104.
40. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-780.
41. Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? better doctors? both? J Clin Oncol. 2003;21:760-761.
42. Herold R, von Stackelberg A, Hartmann R, et al. Acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group (ALL-REZ BFM) experience: early treatment intensity makes the difference. J Clin Oncol. 2004;22:569-570.